Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference
31 Agosto 2022 - 3:30PM
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a
dermatology therapeutics company developing medications for skin
diseases requiring medical interventions, today announced that Ted
White, Verrica President and CEO, will present at the H.C.
Wainwright 24th Annual Global Investment Conference on Wednesday,
September 14, 2022 at 3:30 p.m. ET.
Participants may access a live webcast of the
event through the following link:
https://journey.ct.events/view/f4644667-cfc0-4e04-9eea-ad7eb829da8e.
The webcast can also be accessed in the
Investors/Presentations & Events section of the Verrica website
at www.verrica.com. The webcast replay will be available
shortly after conclusion of the event for 30 days.
About Verrica Pharmaceuticals
Inc.
Verrica is a dermatology therapeutics company
developing medications for skin diseases requiring medical
interventions. Verrica’s late-stage product candidate, VP-102, is
in development to treat molluscum contagiosum, common warts and
external genital warts, three of the largest unmet needs in medical
dermatology. The Company has also entered a worldwide license
agreement with Lytix Biopharma AS to develop and commercialize
LTX-315 for dermatologic oncology conditions. For more information,
visit www.verrica.com.
FOR MORE INFORMATION, PLEASE
CONTACT:
Investors:
Terry Kohler Chief Financial
Officer 484.453.3296 info@verrica.com
William Windham Solebury Trout
646.378.2946 wwindham@soleburytrout.com
Media:
Zara Lockshin Solebury Trout
646.378.2960 zlockshin@soleburytrout.com
Verrica Parmaceuticals (NASDAQ:VRCA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Verrica Parmaceuticals (NASDAQ:VRCA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024